<DOC>
	<DOCNO>NCT01848561</DOCNO>
	<brief_summary>This registry study evaluate long-term safety effectiveness adalimumab patient moderately severely active UC treat recommended product label .</brief_summary>
	<brief_title>A Long-Term Registry HumiraÂ® ( Adalimumab ) Patients With Moderately Severely Active Ulcerative Colitis ( UC )</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>For enrollment HUMIRA treatment group ; adult patient moderately severely active UC prescribe HUMIRA therapy accord routine clinical practice meet one following : 1 . Is currently take HUMIRA therapy receive least 8 week therapy ; OR 2 . Is enter participation Abbott AbbVie sponsor UC study ; receive continuous HUMIRA therapy since initiation therapy For enrollment IMM treatment group ; adult patient moderately severely active UC prescribe IMM therapy , currently take IMM therapy , receive least 12 consecutive week IMM therapy Patients capable willing grant authorization use/disclosure data collect provided AbbVie prior registryrelated data collect , comply requirement Registry protocol Patients IMM therapy without concurrent biologic continue treat IMM therapy Patients treat investigational agent and/or approve biologics Humira .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Inflammatory Bowel Diseases</keyword>
	<keyword>Gastroenteritis</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>Registry</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Colitis</keyword>
</DOC>